Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Manufacturers Face A ‘Phenomenal Challenge’ In Navigating EU AI Act Regulatory Maze

Executive Summary

The European Commission’s proposed Artificial Intelligence Act has undergone some adaptations over the past year, but concerns remain around its impact on the medtech sector. In this interview, Philips’ Koen Cobbaert outlines the current situation and challenges.

You may also be interested in...

Clinical Evidence Requirements For AI Must Be Based On Purpose, EU Expert Group Says

EU guidance on clinical evidence requirements for medical device software does not yet include AI-specific information. An expert group explains how regulators can determine how much evidence is needed for AI-based devices and why common standards should be utilized.

Which Parts Of The EU AI Act Are Unsuitable For Medtech?

Many computer science experts believe that the European Commission’s proposed AI Act is too legislatively heavy. In the second of a two-part interview series, Philips’ Koen Cobbaert explains what parts of the draft legislation are most troublesome for medtech.

How The EU Needs To Address Conflicts Between AI And Medical Device Rules: Part 1

There are serious concerns about how the EU’s proposal for a new Artificial Intelligence Act could disrupt the regulation and supply of medical devices in a few years. Royal Philips’ Koen Cobbaert, explains the challenges in detail in this first part of a two-part interview piece.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts